CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis.
Current pharmaceutical design, 29(39): 3166-3169 PMID 38058090 DOI 10.2174/0113816128267417231127070901
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.